SCHEMBL28048186

SCHEMBL28048186

O=C(O)c1nccc(F)c1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.55
ASPH Q12797 3/20 0.55
KDM8 Q8N371 3/20 0.55
MAPT P10636 4/20 0.44
ALDH1A1 P00352 4/20 0.44
ALB P02768 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
BLM P54132 1/20 0.44
AGER Q15109 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP1A2 P05177 1/20 0.39
NAPRT Q6XQN6 1/20 0.38
KMO O15229 5/20 0.37
MYC P01106 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM6B O15054 1/20 0.35
TET3 O43151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644769 0.81 KDM4E (0.68) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL10373429 0.79 KDM4E (0.60) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL1332334 0.78 KDM4E (0.48) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL28177119 0.78 KDM4E (0.53) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL28337894 0.78 KDM4E (0.58) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL28478885 0.78 KDM4E (0.53) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL25036857 0.77 L3MBTL1 (0.46) KDM4EASPHKDM8ALDH1A1NPSR1
SCHEMBL19857460 0.77 KDM4E (0.62) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL14167699 0.76 KDM4E (0.51) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL4443123 0.75 KDM4E (0.46) KDM4EASPHKDM8MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 US disclosed
WO-2025137640-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-26 WO disclosed
WO-2024255765-A1 NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) 2024-12-19 WO disclosed
CN-105164121-A Perfluorinated cyclopropyl-fused 1, 3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use thereof AMGEN INC 2015-12-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM KDM4E 3650/4885ASPH 4242/4885KDM8 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.